Cytochrome P450 and Its Role in Veterinary Drug Interactions

Veterinary Clinics of North America - Small Animal Practice

Volumn 36, Issue 5, 2006, Pages 975-985

  Trepanier, Lauren A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CHLORAMPHENICOL; CHLORZOXAZONE; CIMETIDINE; CYCLOSPORIN; CYTOCHROME; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B11; CYTOCHROME P450 2C21; CYTOCHROME P450 2C41; CYTOCHROME P450 2D15; CYTOCHROME P450 2E; CYTOCHROME P450 3A12; CYTOCHROME P450 3A26; DIAZEPAM; DICLOFENAC; DIGOXIN; ENZYME; KETOCONAZOLE; MIDAZOLAM; NIFEDIPINE; PHENOBARBITAL; PROPOFOL; PROPRANOLOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VETERINARY DRUG;

CAT; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUSTRY; DRUG RESEARCH; DRUG TRANSFORMATION; ENZYME SUBSTRATE; HUMAN; NONHUMAN; PREDICTION; REVIEW;

ANIMALS; CATS; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG INTERACTIONS; HUMANS; VETERINARY DRUGS;

CANIS FAMILIARIS;

EID: 33748541244     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2006.05.003     Document Type: Review

References (81)

1. Nelson D.R., Zeldin D.C., Hoffman S.M., et al. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14 1 (2004) 1-18
2. Graham R.A., Downey A., Mudra D., et al. In vivo and in vitro induction of cytochrome P450 enzymes in beagle dogs. Drug Metab Dispos 30 11 (2002) 1206-1213
3. Eguchi K., Nishibe Y., Baba T., et al. Quantification of cytochrome P450 enzymes (CYP1A1/2, 2B11, 2C21, and 3A12) in dog liver microsomes by enzyme-linked immunosorbent assay. Xenobiotica 26 7 (1996) 755-763
4. Lu C., and Li A. Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem Biol Interact 134 (2001) 271-281
5. Fuhr U., Anders E.M., Mahr G., et al. Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother 36 5 (1992) 942-948
6. Thomson A.H., Thomson G.D., Hepburn M., et al. A clinically significant interaction between ciprofloxacin and theophylline. Eur J Clin Pharmacol 33 4 (1987) 435-436
7. Nix D.E., DeVito J.M., Whitbread M.A., et al. Effect of multiple dose oral ciprofloxacin on the pharmacokinetics of theophylline and indocyanine green. J Antimicrob Chemother 19 2 (1987) 263-269
8. Wijnands W.J., and Vree T.B. Interaction between the fluoroquinolones and the bronchodilator theophylline. J Antimicrob Chemother 22 Suppl C (1988) 109-114
9. Spivey J.M., Laughlin P.H., Goss T.F., et al. Theophylline toxicity secondary to ciprofloxacin administration. Ann Emerg Med 20 10 (1991) 1131-1134
10. Hirt R.A., Teinfalt M., Dederichs D., et al. The effect of orally administered marbofloxacin on the pharmacokinetics of theophylline. J Vet Med A Physiol Pathol Clin Med 50 5 (2003) 246-250
11. Intorre L., Mengozzi G., Maccheroni M., et al. Enrofloxacin-theophylline interaction: influence of enrofloxacin on theophylline steady-state pharmacokinetics in the beagle dog. J Vet Pharmacol Ther 18 5 (1995) 352-356
12. Visser L.E., van Schaik R.H., van Vliet M., et al. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Clin Pharmacol Ther 77 6 (2005) 479-485
13. van Dijk K.N., Plat A.W., van Dijk A.A., et al. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype. Thromb Haemost 91 1 (2004) 95-101
14. Niwa T., Shiraga T., and Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 28 9 (2005) 1805-1808
15. Black D.J., Kunze K.L., Wienkers L.C., et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 24 4 (1996) 422-428
16. Allison Jr. E.J., McKinney T.J., and Langenberg J.N. Spinal epidural haematoma as a result of warfarin/fluconazole drug interaction. Eur J Emerg Med 9 2 (2002) 175-177
17. Mootha V.V., Schluter M.L., and Das A. Intraocular hemorrhages due to warfarin fluconazole drug interaction in a patient with presumed Candida endophthalmitis. Arch Ophthalmol 120 1 (2002) 94-95
18. Blaisdell J., Goldstein J., and Bai S. Isolation of a new canine cytochrome P450 cDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metab Dispos 26 (1998) 278-283
19. Shou M., Norcross R., Sandig G., et al. Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes P450. Drug Metab Dispos 31 9 (2003) 1161-1169
20. Graham M.J., Bell A.R., Crewe H.K., et al. mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates. Xenobiotica 33 3 (2003) 225-237
21. Desta Z., Wu G.M., Morocho A.M., et al. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos 30 3 (2002) 336-343
22. Pedersen R.S., Damkier P., and Brosen K. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin Pharmacol Ther 77 6 (2005) 458-467
23. Caraco Y., Sheller J., and Wood A.J. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J Pharmacol Exp Ther 290 1 (1999) 413-422
24. Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D 6 3 (2005) 174-177
25. Tasaki T., Nakamura A., Itoh S., et al. Expression and characterization of dog CYP2D15 using baculovirus expression system. J Biochem (Tokyo) 123 1 (1998) 162-168
26. Paulson S.K., Engel L., Reitz B., et al. Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metab Dispos 27 10 (1999) 1133-1142
27. Dresser G.K., Spence J.D., and Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38 1 (2000) 41-57
28. Lam Y.W., Alfaro C.L., Ereshefsky L., et al. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol 43 11 (2003) 1274-1282
29. Sakaeda T., Iwaki K., Kakumoto M., et al. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol 57 6 (2005) 759-764
30. Raaska K., Niemi M., Neuvonen M., et al. Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. Clin Pharmacol Ther 72 4 (2002) 362-369
31. Bolland M.J., Bagg W., Thomas M.G., et al. Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole. Ann Pharmacother 38 1 (2004) 46-49
32. Zhou S., Chan E., Lim L.Y., et al. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 5 5 (2004) 415-442
33. Maskalyk J. Grapefruit juice: potential drug interactions. CMAJ 167 3 (2002) 279-280
34. Jayyosi Z., Muc M., Erick J., et al. Catalytic and immunochemical characterization of cytochrome P450 enzyme induction in dog liver. Fundam Appl Toxicol 31 (1996) 95-102
35. Nishibe Y., Wakabayashi M., Harauchi T., et al. Characterization of cytochrome P450 (CYP3A12) induction by rifampicin in dog liver. Xenobiotica 28 (1998) 549-557
36. Lu P., Singh S.B., Carr B.A., et al. Selective inhibition of dog hepatic CYP2B11 and CYP3A12. J Pharmacol Exp Ther 313 2 (2005) 518-528
37. Kuroha M., Azumano A., Kuze Y., et al. Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P450 3A substrate in beagle dogs. Drug Metab Dispos 30 (2002) 63-68
38. He Y., Roussel F., and Halpert J. Importance of amino acid residue 474 for substrate specificity of canine and human cytochrome P450 3A enzymes. Arch Biochem Biophys 389 2 (2001) 264-270
39. Fraser D., Feyereisen R., Harlow G., et al. Isolation, heterologous expression, and functional characterization of a novel cytochrome P450 3A enzyme from a canine liver cDNA library. J Pharmacol Exp Ther 283 (1997) 1425-1432
40. Patricelli A.J., Hardie R.J., and McAnulty J.E. Cyclosporine and ketoconazole for the treatment of perianal fistulas in dogs. J Am Vet Med Assoc 220 7 (2002) 1009-1016
41. McAnulty J.F., and Lensmeyer G.L. The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. Vet Surg 28 6 (1999) 448-455
42. Kim E.J., Seo J.W., Hwang J.Y., et al. Effects of combined treatment with sildenafil and itraconazole on the cardiovascular system in telemetered conscious dogs. Drug Chem Toxicol 28 2 (2005) 177-186
43. Sahi J., Reyner E.L., Bauman J.N., et al. The effect of bergamottin on diazepam plasma levels and P450 enzymes in beagle dogs. Drug Metab Dispos 30 2 (2002) 135-140
44. Amatori F.M., Meucci V., Giusiani M., et al. Effect of grapefruit juice on the pharmacokinetics of cyclosporine in dogs. Vet Rec 154 6 (2004) 180-181
45. Mealey K.L. Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther 27 5 (2004) 257-264
46. Collett A., Tanianis-Hughes J., Carlson G.L., et al. Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction. Eur J Pharm Sci 26 5 (2005) 386-393
47. Sartor L.L., Bentjen S.A., Trepanier L., et al. Loperamide toxicity in a collie with the MDR1 mutation associated with ivermectin sensitivity. J Vet Intern Med 18 1 (2004) 117-118
48. Mealey K.L., Bentjen S.A., Gay J.M., et al. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 11 8 (2001) 727-733
49. Mealey K.L., Northrup N.C., and Bentjen S.A. Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. J Am Vet Med Assoc 223 10 (2003) 1434, 1453-5
50. Martinez C., Albet C., Agundez J.A., et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther 65 4 (1999) 369-376
51. Furuta S., Kamada E., Suzuki T., et al. Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica 31 1 (2001) 1-10
52. Fraser I.M., Buttoo K.M., Walker S.E., et al. Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). Clin Ther 15 2 (1993) 383-393
53. Loi C.M., Parker B.M., Cusack B.J., et al. Aging and drug interactions. III. Individual and combined effects of cimetidine and cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers. J Pharmacol Exp Ther 280 2 (1997) 627-637
54. Ohashi K., Sakamoto K., Sudo T., et al. Effects of diltiazem and cimetidine on theophylline oxidative metabolism. J Clin Pharmacol 33 12 (1993) 1233-1237
55. Nix D.E., Di Cicco R.A., Miller A.K., et al. The effect of low-dose cimetidine (200 mg twice daily) on the pharmacokinetics of theophylline. J Clin Pharmacol 39 8 (1999) 855-865
56. Choonara I.A., Cholerton S., Haynes B.P., et al. Stereoselective interaction between the R enantiomer of warfarin and cimetidine. Br J Clin Pharmacol 21 3 (1986) 271-277
57. Feely J., Collins W.C., Cullen M., et al. Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists. Br J Clin Pharmacol 35 3 (1993) 321-323
58. Ishii Y., Nakamura K., Tsutsumi K., et al. Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers. J Clin Pharmacol 40 2 (2000) 193-199
59. Daigle J.C., Hosgood G., Foil C.S., et al. Effect of cimetidine on pharmacokinetics of orally administered cyclosporine in healthy dogs. Am J Vet Res 62 7 (2001) 1046-1050
60. Johnson L.M., Lankford S.M., and Bai S.A. The influence of cimetidine on the pharmacokinetics of the enantiomers of verapamil in the dog during multiple oral dosing. J Vet Pharmacol Ther 18 2 (1995) 117-123
61. Ritschel W.A., Banerjee P.S., Cacini W., et al. Animal model for theophylline-cimetidine drug interaction. Methods Find Exp Clin Pharmacol 7 12 (1985) 627-629
62. Chen C.S., Lin J.T., Goss K.A., et al. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol 65 5 (2004) 1278-1285
63. Hay-Kraus B., Greenblatt D., Venkatakrishnan K., et al. Evidence of propofol hydroxylation by cytochrome P4502B11 in canine liver microsomes: breed and gender differences. Xenobiotica 30 6 (2000) 575-588
64. Ciaccio P., Duignan D., and Halpert J. Selective inactivation by chloramphenicol of the major phenobarbital-inducible isozyme of dog liver cytochrome P450. Drug Metab Dispos 15 6 (1987) 852-856
65. Mandsager R., Clarke C., Shawley R., et al. Effects of chloramphenicol on infusion pharmacokinetics of propofol in Greyhounds. Am J Vet Res 56 1 (1995) 95-99
66. Adams H.R., and Dixit B.N. Prolongation of pentobarbital anesthesia by chloramphenicol in dogs and cats. J Am Vet Med Assoc 156 7 (1970) 902-905
67. Sanders J.E., Yeary R.A., Fenner W.R., et al. Interaction of phenytoin with chloramphenicol or pentobarbital in the dog. J Am Vet Med Assoc 175 2 (1979) 177-180
68. Teske R.H., and Carter G.G. Effect of chloramphenicol on pentobarbital-induced anesthesia in dogs. J Am Vet Med Assoc 159 6 (1971) 777-780
69. Graham R., Downey A., Mudra D., et al. In vivo and in vitro induction of cytochrome P450 enzymes in beagle dogs. Drug Metab Dispos 30 (2002) 1206-1213
70. Tanaka N., Shinkyo R., Sakaki T., et al. Cytochrome P450 2E polymorphism in feline liver. Biochim Biophys Acta 1726 2 (2005) 194-205
71. Truhaut R., Ferrando R., Graillot C., et al. [Induction of cytochrome P 450 by phenobarbital in cats.]. C R Acad Sci Hebd Seances Acad Sci D 286 4 (1978) 371-373 [in French]
72. Born S., Fraser D., Harlow G., et al. Escherichia coli expression and substrate specificities of canine cytochrome P450 3A12 and rabbit cytochrome P450 3A6. J Pharmacol Exp Ther 278 (1996) 957-963
73. Eguchi K., Nishibe Y., Baba T., et al. Quantitation of cytochrome P450 enzymes (CYP1A1/2, 2B11, 2C21 and 3A12) in dog liver microsomes by enzyme-linked immunosorbent assay. Xenobiotica 26 7 (1996) 755-763
74. Lankford S., Bai S., and Goldstein J. Cloning of canine cytochrome P450 2E1 cDNA: identification and characterization of two variant alleles. Drug Metab Dispos 28 (2000) 981-986
75. McLaughlin L.A., Paine M.J., Kemp C.A., et al. Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding. J Biol Chem 280 46 (2005) 38617-38624
76. Roussel F., Duignan D., Lawton M., et al. Expression and characterization of canine cytochrome P450 2D15. Arch Biochem Biophys 357 1 (1998) 27-36
77. Glaeser H., Drescher S., Eichelbaum M., et al. Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. Br J Clin Pharmacol 59 2 (2005) 199-206
78. Kuroha M., Kayaba H., Kishimoto S., et al. Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs. J Pharm Sci 91 3 (2002) 868-873
79. Ravis W.R., Pedersoli W.M., and Turco J.D. Pharmacokinetics and interactions of digoxin with phenobarbital in dogs. Am J Vet Res 48 8 (1987) 1244-1249
80. Breznock E.M. Effects of phenobarbital on digitoxin and digoxin elimination in the dog. Am J Vet Res 36 4 Pt 1 (1975) 371-373
81. Vu V.T., Bai S.A., and Abramson F.P. Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics. J Pharmacol Exp Ther 224 1 (1983) 55-61